Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 3/2010

01-06-2010 | Original Paper

Eliciting health state utilities from the general public for severe chronic pain

Authors: S. Eldabe, A. Lloyd, L. Verdian, M. Meguro, G. Maclaine, S. Dewilde

Published in: The European Journal of Health Economics | Issue 3/2010

Login to get access

Abstract

Objective

There is an absence of data on public preferences for health states (HSs) associated with severe chronic pain. The aim of this study was to develop accurate HS descriptions for severe chronic pain requiring intrathecal (IT) therapy and to derive utility weights that describe the health-related quality of life (HRQL) impact of chronic pain associated with malignant (MP) and non-malignant (NMP) aetiologies.

Research design and method

Eight visual analogue scale pain index (VAS-PI) HSs were defined using ranges 0–40, 41–60, 61–80 and 81–100 applied to both MP and NMP. Additionally, eight HSs representing common adverse events associated with IT therapy were identified. The content and description of the HSs were ascertained by interviews with five United Kingdom clinical experts. In total, 16 HSs were compiled. These HS descriptions and HS questionnaires were administered to 102 members of the public, utilising a time trade off (TTO) approach to estimate utilities for the HSs.

Results

Participants generally were well matched to the general public in England and Wales, with some differences in mean age, race and education. A substantial decline in utility was observed with more severe VAS-PI values. The mean TTO utility values also decreased from mild pain to severe pain. Participants were able to differentiate between the side effects.

Conclusion

The study shows a clear decrement in utility moving from different severity levels of severe chronic pain.
Literature
1.
Gureje, O., Von Korff, M., Simon, G.E., Gater, R.: Persistent pain and well-being: a world health organization study in primary care. JAMA 280, 147–151 (1998)CrossRef
2.
Smith, B.H., Elliott, A.M., Chambers, W.A., Smith, W.C., Hannaford, P.C., Penny, K.: The impact of chronic pain in the community. Fam. Pract. 18, 292–299 (2001)CrossRef
3.
Elliott, A.M., Smith, B.H., Hannaford, P.C., Smith, W.C., Chambers, W.A.: The course of chronic pain in the community: results of a 4-year follow-up study. Pain 99, 299–307 (2002)CrossRef
4.
Turner, J.A., Sears, J.M., Loeser, J.D.: Programmable intrathecal opioid delivery systems for chronic noncancer pain: a systematic review of effectiveness and complications. Clin. J. Pain. 23, 180–195 (2007)CrossRef
5.
Williams, J.E., Louw, G.: Intrathecal pumps for giving opioids in chronic pain: a systematic review. Health Technol. Assess. 4, 1–65 (2000)
6.
Dolan, P.: Modeling valuations for EuroQol health states. Med. Care 35, 1095–1108 (1997)CrossRef
7.
Brazier, J., Roberts, J., Deverill, M.: The estimation of a preference-based single index measure for health from the SF-36. J. Health Econ. 21, 271–292 (2002)CrossRef
8.
McDermott, A.M., Toelle, T.R., Rowbotham, D.J., Schaefer, C.P., Dukes, E.M.: The burden of neuropathic pain: results from a cross-sectional survey. Eur. J. Pain 10, 127–135 (2006)CrossRef
9.
Ackerman, L.L., Follet, K.A.: Long-term outcomes during treatment of chronic pain with intrathecal clonidine or clonidine/opioid combinations. J. Pain Symptom Manage. 26, 668–677 (2003)CrossRef
10.
Anderson, A., Burchiel, K.: A prospective study of long-term intrathecal morphine in the management of chronic nonmalignant pain. Neurosurgery 44, 289–300 (1999)CrossRef
11.
Nitescu, P., Dahm, P., Appelgren, L., Curelaru, I.: Continuous infusion of opioid and bupivacaine by externalized intrathecal catheters in long-term treatment of “refractory” nonmalignant pain. J. Clin. Pharm. 14, 17–28 (1998)
12.
Sjöberg, M., Nitescu, P., Appelgren, L., Curelaru, I.: Long-term intrathecal morphine and bupivacaine in patients with refractory cancer pain. Results from a morphine:bupivacaine dose regimen of 0.5:4.75 mg/ml. Anesthesiology 80, 284–297 (1994)CrossRef
13.
Winkelmüller, M., Winkelmüller, W.: Long-term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology. J. Neurosurg. 85, 458–467 (1996)CrossRef
14.
Carlsson, A.M.: Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale. Pain 16, 87–101 (1997)CrossRef
15.
Price, D.D., McGrath, P.A., Rafii, A., Buckingham, B.: The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain 17, 45–56 (1983)CrossRef
16.
Rauck, R.L., Wallace, M.S., Leong, M.S., Minehart, M., Webster, L.R., Charapata, S.G., Abraham, J.E., Buffington, D.E., Ellis, D., Kartzinel, R.: Ziconotide 301 Study Group: a randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J. Pain Symptom Manage. 31, 393–406 (2006)CrossRef
17.
Staats, P.S., Yearwood, T., Charapata, S.G., Presley, R.W., Wallace, M.S., Byas-Smith, M., Fisher, R., Bryce, D.A., Mangieri, E.A., Luther, R.R., Mayo, M., McGuire, D., Ellis, D.: Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 291, 63–70 (2004)CrossRef
18.
Wermeling, D., Drass, M., Ellis, D., Mayo, M., McGuire, D., O’Connell, D., Hale, V., Chao, S.: Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. J. Clin. Pharmacol. 43, 624–636 (2003)
19.
Atanassoff, P.G., Hartmannsgruber, M.W., Thrasher, J., Wermeling, D., Longton, W., Gaeta, R., Singh, T., Mayo, M., McGuire, D., Luther, R.R.: Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain. Reg. Anesth. Pain. Med. 25, 274–278 (2000)
20.
Brose, W.G., Gutlove, D.P., Luther, R.R., Bowersox, S.S., McGuire, D.: Use of intrathecal SNX-111, a novel, N-type, voltage-sensitive, calcium channel blocker, in the management of intractable brachial plexus avulsion pain. Clin. J. Pain 13, 256–259 (1997)CrossRef
21.
Breivik, H., Collett, B., Ventafridda, V., Cohen, R., Gallacher, D.: Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur. J. Pain 10, 287–333 (2006)CrossRef
22.
Kamran, S., Wright, B.: Complications of intrathecal drug delivery systems. Neuromodulation 4, 111–115 (2001)CrossRef
23.
Mercadante, S.: Controversies over spinal treatment in advanced cancer patients. Support. Care Cancer 6, 495–502 (1998)CrossRef
24.
Naumann, C., Erdine, S., Koulousakis, A., Van Buyten, J.P., Schuchard, M.: Drug adverse events and system complications of intrathecal opioid delivery for pain: origins, detection, manifestations, and management. Neuromodulation 2, 92–107 (2002)CrossRef
25.
Tutak, U., Doleys, D.M.: Intrathecal infusion systems for treatment of chronic low back and leg pain of noncancer origin. South Med. J. 89, 295–300 (1996)CrossRef
26.
Yang, C.Y., Wong, C.S., Chang, J.Y., Ho, S.T.: Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Can. J. Anaesth. 43, 379–383 (1996)CrossRef
27.
Wallace, M.S., Rauck, R., Fisher, R., Charapata, S.G., Ellis, D., Dissanayake, S., Ziconotide 98-022 Study Group: Intrathecal ziconotide for severe chronic pain: safety and tolerability results of an open-label, long-term trial. Anesth. Analg. 106, 628–637 (2008)CrossRef
28.
Wermeling, D.P., Berger, J.R.: Ziconotide infusion for severe chronic pain: case series of patients with neuropathic pain. Pharmacotherapy 26, 395–402 (2006)CrossRef
29.
Kind, P.: The EuroQoL instrument: an index of health-related quality of life. In: Spilker, B. (ed.) Quality of Life and Pharmacoeconomics in Clinical Trials, pp. 191–203. Lippincott-Raven, Philadelphia (1996)
30.
The EuroQol Group: EuroQol–a new facility for the measurement of health-related quality of life. Health Policy 16, 199–208 (1990)
31.
Bennett, K., Torrance, G.: Measuring health state preferences and utilities: Rating scale, time trade-off and standard gamble techniques. In: Spilker, B. (ed.) HRQL and Pharmacoeconomics in Clinical Trials, pp. 253–266. Lippincott-Rave, Philadelphia (1996)
32.
33.
34.
Lai, K.C., Provenzale, J.M., Delong, D., Mukundan, S, Jr: Assessing patient utilities for varying degrees of low back pain. Acad. Radiol. 12, 467–474 (2005)CrossRef
35.
Roland, M., Morris, R.: A study of the natural history of low-back pain. Part II: development of guidelines for trials of treatment in primary care. Spine 8, 145–150 (1983)CrossRef
36.
Roland, M., Morris, R.: A study of the natural history of back pain. Part I: development of a reliable and sensitive measure of disability in low-back pain. Spine 8, 141–144 (1983)CrossRef
Metadata
Title
Eliciting health state utilities from the general public for severe chronic pain
Authors
S. Eldabe
A. Lloyd
L. Verdian
M. Meguro
G. Maclaine
S. Dewilde
Publication date
01-06-2010
Publisher
Springer-Verlag
Published in
The European Journal of Health Economics / Issue 3/2010
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-009-0178-x

Other articles of this Issue 3/2010

The European Journal of Health Economics 3/2010 Go to the issue

Pricing and reimbursement systems in Europe

The Irish ‘health basket’: a basket case?

Original Paper

The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany

Original Paper

Pharmaceutical penetration of new drug and pharmaceutical market structure in Taiwan: hospital-level prescription of thiazolidinediones for diabetes

Original Paper

The impact of missing data in the estimation of concentration index: a potential source of bias

Editorial

Future challenges for health economics and health technology assessment of biological drugs

Original Paper

Copayments for ambulatory care in Germany: a natural experiment using a difference-in-difference approach